23 Sept. Concert Pharmaceuticals - CF
By replacing a single hydrogen atom with deuterium in a 3-year-old cystic fibrosis drug developed by Vertex Pharmaceuticals, Lexington-based Concert Pharmaceuticals says it was able to show the altered version works better in a small, early-stage clinical trial.
PEOPLE ON THE MOVE
Earl Faulk
Earl Faulk
Erland Construction, Inc.
Byron R. Ford, Jr.
Byron R. Ford, Jr.
WEICHERT, REALTORS® - Mel Antonio Group
Timothy Keshian
Timothy Keshian
Coretelligent
See More People on the Move
Investors celebrated the news, announced by Concert (Nasdaq: CNCE) last night, by pushing the company's stock up 21 percent to an all-time high. As of this afternoon, shres in the 55-employee company, which went public in February 2014, were trading at $22 apiece, giving the company a market value of $482 million.
-- geen idee of dit veel betekenis heeft--